OTC: IDRSF - Idorsia Ltd

半年間の収益性: -59.46%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Idorsia Ltd

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

さらに詳しく
Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета chf
Сайт https://www.idorsia.com
Цена ао 1.15
1日あたりの価格変動: 0% (1.05)
週ごとの価格変動: -19.85% (1.31)
月ごとの料金変更: +40% (0.75)
3ヶ月間の価格変動: +50% (0.7)
半年間の価格変動: -59.46% (2.59)
年間の価格変動: -60.23% (2.64)
3年間の価格推移: -94.21% (18.15)
5年間の価格推移: -96.18% (27.5)
年初からの価格変動: +50% (0.7)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 2.3 6
P/BV -0.3623 0
P/E 0 0
EV/EBITDA -2.69 0
合計: 4.38

効率

名前 意味 学年
ROA, % -59.58 0
ROE, % 30.75 9
合計: 3.17

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -2.17 10
合計: 9.2

成長の衝動

名前 意味 学年
収益性 Revenue, % 539.77 10
収益性 Ebitda, % -44.99 0
収益性 EPS, % -55.07 0
合計: 3
さらに詳しく

機関 音量 共有, %
Fidelity Select Portfolios - Biotechnology 4866770 2.58
Smallcap World Fund 2270994 1.2
Vanguard International Stock Index-Total Intl Stock Indx 1627551 0.86
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 958060 0.51
iShares Core MSCI EAFE ETF 628695 0.33
Fidelity Growth Company Fund 623409 0.33
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 479318 0.25
iShares MSCI EAFE Small Cap ETF 426739 0.23
Vanguard International Stock Index-Vanguard European Stock Index 252174 0.13
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 238962 0.13



スーパーバイザー 役職 支払い 生年
Mr. Jean-Paul Clozel M.D. CEO & Chairman of the Board 956.86k 1955 (70 年)
Dr. Martine Clozel Executive VP & Chief Scientific Officer N/A 1955 (70 年)
Mr. Andrew C. Weiss Senior VP and Head of Investor Relations & Corporate Communications N/A 1968 (57 年)
Mr. Julien Gander L.L.M. Senior VP, Group General Counsel & Company Secretary N/A 1979 (46 年)
Mr. Alexander Khatuntsev Senior VP & Head of Global Human Resources N/A 1978 (47 年)
Dr. Guy Braunstein M.D. Executive VP & Chief Medical Officer N/A 1956 (69 年)
Mr. Olivier Lambert Senior VP & Head of Technical Operations N/A 1966 (59 年)
Mr. Markus A. Riederer Senior VP & Head of Drug Discovery Biology N/A 1962 (63 年)
Mr. Alberto Gimona M.D. Executive VP & Head of Global Clinical Development N/A 1960 (65 年)
Mr. Andre C. Muller Executive VP & CFO 1963 (62 年)

住所: Switzerland, Allschwil, Hegenheimermattweg 91 - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.idorsia.com